Atossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen

MT Newswires Live01-30

Atossa Therapeutics (ATOS) said Thursday it will not appeal a US Patent Trial and Appeal Board decision that invalidated claims in one of its patents but will continue pursuing new patent protections for its clinical-stage formulations.

In August 2023, Atossa said Intas Pharmaceuticals had filed a Post Grant Review application for Atosaa's patent covering methods for making and using endoxifen.

The company said Thursday that the PTAB ruled that all challenged claims in US Patent No. 11,572,334 were unpatentable, adding that the decision does not affect its current clinical formulations and that it plans to file a continuation patent application.

Atossa also said it was granted a new patent covering sustained-release compositions of endoxifen.

Atossa shares were 9% lower in early trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2507629754?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-30 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507629754","market":"fut","top_or_hot":-1,"title":"Atossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen","media":"MT Newswires Live","content":"<html><body><p> Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ATOS) said Thursday it will not appeal a US Patent Trial and Appeal Board decision that invalidated claims in one of its patents but will continue pursuing new patent protections for its clinical-stage formulations.</p><p>In August 2023, Atossa said Intas Pharmaceuticals had filed a Post Grant Review application for Atosaa's patent covering methods for making and using endoxifen.</p><p>The company said Thursday that the PTAB ruled that all challenged claims in US Patent No. 11,572,334 were unpatentable, adding that the decision does not affect its current clinical formulations and that it plans to file a continuation patent application.</p><p>Atossa also said it was granted a new patent covering sustained-release compositions of endoxifen.</p><p>Atossa shares were 9% lower in early trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-30 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ATOS) said Thursday it will not appeal a US Patent Trial and Appeal Board decision that invalidated claims in one of its patents but will continue pursuing new patent protections for its clinical-stage formulations.</p><p>In August 2023, Atossa said Intas Pharmaceuticals had filed a Post Grant Review application for Atosaa's patent covering methods for making and using endoxifen.</p><p>The company said Thursday that the PTAB ruled that all challenged claims in US Patent No. 11,572,334 were unpatentable, adding that the decision does not affect its current clinical formulations and that it plans to file a continuation patent application.</p><p>Atossa also said it was granted a new patent covering sustained-release compositions of endoxifen.</p><p>Atossa shares were 9% lower in early trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507629754","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507629754","pubTimestamp":1738247937,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Atossa Therapeutics  said Thursday it will not appeal a US Patent Trial and Appeal Board decision that invalidated claims in one of its patents but will continue pursuing new patent protections for its clinical-stage formulations.In August 2023, Atossa said Intas Pharmaceuticals had filed a Post Grant Review application for Atosaa's patent covering methods for making and using endoxifen.The company said Thursday that the PTAB ruled that all challenged claims in US Patent No. 11,572,334 were unpatentable, adding that the decision does not affect its current clinical formulations and that it plans to file a continuation patent application.Atossa also said it was granted a new patent covering sustained-release compositions of endoxifen.Atossa shares were 9% lower in early trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATOS":"Atossa Genetics Inc","LENZ":"Therapeutics"},"translate_title":"Atossa Therapeutics不会对PTAB关于Endoxifen专利审查的决定提出上诉","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATOS":0.9,"LENZ":1},"content_text":"Atossa Therapeutics (ATOS) said Thursday it will not appeal a US Patent Trial and Appeal Board decision that invalidated claims in one of its patents but will continue pursuing new patent protections for its clinical-stage formulations.In August 2023, Atossa said Intas Pharmaceuticals had filed a Post Grant Review application for Atosaa's patent covering methods for making and using endoxifen.The company said Thursday that the PTAB ruled that all challenged claims in US Patent No. 11,572,334 were unpatentable, adding that the decision does not affect its current clinical formulations and that it plans to file a continuation patent application.Atossa also said it was granted a new patent covering sustained-release compositions of endoxifen.Atossa shares were 9% lower in early trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2507629754"}